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Reply
It is with pleasure that I respond to Dr Arko’s letter regarding
our recent publication on endograft migration.1 As per his request,
a Kaplan-Meier analysis for freedom from migration is presented in
the figure. Risk of endograft migration was approximately 23%,
32%, and 45% at 30, 36, and 48 months, respectively, similar to our
previously published data of 20.4% and 42.1% at 24 and 36
months, respectively. As explicitly stated in the original manu-
script, the 48-month estimates must be considered preliminary
because of the small number of patients at this time point. No
patients were “counted twice”2 in the calculation of migration
rates (Figure).
The inference that migration occurred primarily because of
“low” initial placement of the endograft2 is not supported by the
data. Migrators and nonmigrators in our study had similar aortic
neck/endograft overlap (18.6 mm vs 19.4 mm) and initial distance
from the lowest renal artery (7.3 mm vs 7.6 mm, respectively, P
.8).1 If this hypothesis had merit, those patients who migrated
should have demonstrated a shorter overlap. Moreover, the initial
aortic neck/endograft overlap was substantially longer than the
minimum aortic neck length required in the multicenter trial (10
mm) or currently suggested by Medtronic (15 mm). To my
knowledge, there have been no other prospectively collected data
published on accuracy of proximal endograft placement, and I
would invite other investigators to examine and report their re-
sults.
Placement of the endograft immediately below the most cau-
dal renal artery is clearly ideal but in practice may not always occur.
The Stanford group’s “better technique”2 to attain this goal still
resulted in a 20% (16/79) need for immediate aortic cuff place-
ment during endograft insertion for presumed initial malplace-
ment or intraoperative distal migration.3 At Ochsner, our need for
such acute adjunctive measures has been only 3% (4/129). How-
ever, current accuracy of endograft placement is likely better than
was reported in the early experience with this technology.
The most important finding of our study may have been that
aortic neck dilation was highly correlated with endograft migra-
tion. While initial aortic neck diameters were similar (21.5 mm 
0.6 mm vs 21.8 mm 0.3 mm, P .6), migrators had significant
late aortic neck dilation that was not seen in nonmigrators (P 
.05). Other investigators have also noted a correlation of late aortic
neck dilation with endograft migration.4 As warned by Dr Szilagyi5
and borne out at late open conversions of this device, there is little
healing or incorporation of the proximal end of endografts with
the aorta. As such, an endograft largely relying on an infrarenal
friction seal will have a high risk of distal migration if the aortic
neck dilates. This anatomic reality, more than anything else, is the
best explanation for the migration rate seen with the AneuRx
device. The potential fixation instability of this device has been
echoed in two recent editorials written by investigators with sub-
stantial endograft experience.6,7
These data-driven observations from our study and others
force me to disagree with Dr Arko that “migration is prevent-
able. . .”2 with the AneuRx device. While prudent patient selection
and procedural placement accuracy are indeed essential in optimiz-
ing results, the risk of migration is unlikely to be prevented unless
there is no late aortic neck dilation. Regrettably, progressive aortic
neck dilation does occur in some patients after endovascular or
open AAA repair.1,8,9
The inference that our experience with migration is a single-
center aberration is at odds with reports from other experienced
investigators who have also observed a significant rate of endograft
migration with this device.4,7,10,11 Most recently, Dr Zarins re-
ported migration rates of approximately 19% at 36 months and
25% to 30% at 40 months (Kaplan-Meier analysis) from 1119
patients in the AneuRx multicenter trial.12 These migration rates
are similar to our single center experience.
Our reported migration treatment incidence of 5.4% (5/91)
underscores that the true migration rate, as reported in our study,
is higher than the number of treated patients at any given time
point. Since submission of our manuscript, treatment of an addi-
tional seven patients for AneuRx device migration has been re-
quired (12 total, 13.2%). To date, 10 have been treated with aortic
cuffs, 1 with aorto-uni-iliac endovascular conversion, and 1 with
open conversion.
As detailed by Dr Robert Rutherford, the true incidence of
adverse events relating to endovascular treatment of AAA can be
difficult to judge; access to industry-sponsored trial data has been
frequently restricted to selected investigators and not pub-
lished.14,15 These realities prompted a substantial overhaul in the
author responsibilities for publishing such industry-sponsored
work in the Journal of Vascular Surgery16 and other leading jour-
nals. Differing interpretation of data is an integral and healthy part
of the scientific process, but the data must be widely disseminated
for such discourse to occur. As clinical investigators with early
access to devices, we have a responsibility to other treating physi-
cians and their patients to candidly report late failure modes. We
may recognize such events long before they are widely evident.
Supplied with such data, practitioners can then decide what are the
best treatment options for their patients.
W. Charles Sternbergh III, MD
Program Director, Vascular Surgery
Ochsner Clinic Foundation
New Orleans, La
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